首页> 美国卫生研究院文献>Journal of Pharmaceutical Policy and Practice >Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries
【2h】

Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries

机译:外部价格参考对药品价格的影响–欧洲14个国家之间的价格比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objectives: This study aims to examine the impact of external price referencing (EPR) on on-patent medicine prices, adjusting for other factors that may affect price levels such as sales volume, exchange rates, gross domestic product (GDP) per capita, total pharmaceutical expenditure (TPE), and size of the pharmaceutical industry.Methods: Price data of 14 on-patent products, in 14 European countries in 2007 and 2008 were obtained from the Pharmaceutical Price Information Service of the Austrian Health Institute. Based on the unit ex-factory prices in EURO, scaled ranks per country and per product were calculated. For the regression analysis the scaled ranks per country and product were weighted; each country had the same sum of weights but within a country the weights were proportional to its sales volume in the year (data obtained from IMS Health). Taking the scaled ranks, several statistical analyses were performed by using the program “R”, including a multiple regression analysis (including variables such as GDP per capita and national industry size).Results: This study showed that on average EPR as a pricing policy leads to lower prices. However, the large variation in price levels among countries using EPR confirmed that the price level is not only driven by EPR. The unadjusted linear regression model confirms that applying EPR in a country is associated with a lower scaled weighted rank (p=0.002). This interaction persisted after inclusion of total pharmaceutical expenditure per capita and GDP per capita in the final model. Conclusions: The study showed that for patented products, prices are in general lower in case the country applied EPR. Nevertheless substantial price differences among countries that apply EPR could be identified. Possible explanations could be found through a correlation between pharmaceutical industry and the scaled price ranks. In conclusion, we found that implementing external reference pricing could lead to lower prices.
机译:目标:本研究旨在研究外部价格参考(EPR)对专利药品价格的影响,并调整可能影响价格水平的其他因素,例如销量,汇率,人均国内生产总值(GDP),总量方法:2007年和2008年欧洲14个国家/地区14种在售专利产品的价格数据是从奥地利卫生研究院的药品价格信息服务获得的。根据欧元单位出厂价,计算出每个国家和每种产品的按比例排名。为了进行回归分析,加权了每个国家和产品的等级等级;每个国家/地区的权重总和都相同,但在一个国家/地区内,权重与当年的销量成正比(数据来自IMS Health)。以等级排序,使用“ R”程序进行了一些统计分析,包括多元回归分析(包括人均GDP和国家行业规模等变量)。结果:这项研究表明,平均EPR作为定价政策导致价格降低。但是,使用EPR的国家之间价格水平的巨大差异证实了价格水平不仅是由EPR驱动的。未经调整的线性回归模型证实,在一个国家/地区应用EPR与较低的加权加权等级相关(p = 0.002)。在最终模型中将人均医药总支出和人均GDP包括在内之后,这种相互作用仍然存在。结论:研究表明,专利产品的价格一般会在该国采用EPR的情况下降低。然而,可以确定实行EPR的国家之间存在实质性的价格差异。可能的解释可以通过制药行业和按比例划分的价格等级之间的相关性找到。总之,我们发现实施外部参考定价可能会导致价格下降。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号